Abstract
The objective of this study was to determine the pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus (HIV) infection. After an overnight fast, a single dose of either 2 mg·kg−1 or 8 mg·kg−1 was administered in a suspension; five children received 2 mg·kg−1 and four 8 mg·kg−1 (ages 5–13 years). Blood samples were collected at various times on day 1, and once daily on days 2–7 after the dose. Fluconazole serum concentrations were measured by gas chromatography. At the dose of 2 mg·kg−1, the Cmax, AUC (0–∞), and t1/2 ranged from 2.3–4.4 μg·ml−1, 84.9–136 μg·h·ml−1, and 19.8–34.8 h, respectively. At the dose of 8 mg·kg−1 the Cmax, AUC (0–∞), and t1/2 ranged from 5.4–12.1 μg·ml−1, 330–684 μgh·ml−1, and 25.6–42.3 h, respectively. When compared with published data in healthy adults, fluconazole achieved similar serum concentrations in the present group of children, indicating a nearly complete degree of absorption.
Similar content being viewed by others
References
Debruyne D, Ryckelynck J (1993) Clinical pharmacokinetics of fluconazole. Clin Pharm 24:10–27
Grant SM, Clissold SP (1990) Fluconazole — a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycosis. Drugs 39:877–916
Stern JJ, Harman BJ, Sharkey P, Rowland V, Squires K, Murray HW, Graybill JR (1988) Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 85:477–480
Sugar AM, Saunders C (1988) Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 85:481–489
DeWit S, Urbain D, Rahir F, Weerts D, Clumeck N (1991) Efficacy of oral fluconazole in the treatment of AIDS associated oesophageal candidiasis. Eur J Clin Microbiol Infect Dis 10:503–505
Lake-Bakaar, Beidas S, Elsakr M, Iyer S, Staus E (1987) Impaired gatric acid secretion in AIDS. Gastroenterology 92:1488A
Guttman D, Raymond JA, Gelb A, Ehya H, Mather U, Mildran D, et al (1983) Virus-associated colitis in homosexual men: two case reports. Am J Gastroenterol 78:167–169
Kotler DP, Gaetz HP, Lange (1984) Enteropathy associated with the acquired immunodeficiency syndrome. Ann Int Med 101:421–428
Levinson W, Bennetts RW (1985) Cytomegalovirus colitis is acquired immunodeficiency syndrome — a chronic disease with varying manifestations. Am J Gastroenterol 80:445–447
Harris SC, Wallace JE, Foulds G, Rinaldi MG (1989) Assay of fluconazole by megabore capillary gas liquid chromatography with nitrogen selective detecttion. Antimicrob Agents Chemother 33:714–716
Farrow PR, Faulkner JK, Brammer KW (1988) The pharmacokinetics of fluconazole. Symposium on fluconazole: a novel advance in therapy for systemic fungal infections, Dorado, Puerto Rico, Oct 8–9, abstract no. 14-199
Foulds G, Wajszczuk C, Weidler DJ, Garg DC, Gibso P (1987) Steady state parenteral kinetics of fluconazole in man. First International Conference on Drug Research in Immunologic and Infectious Diseases: antifungal drugs, Oct 8–10 abstract no. P-6
Hughes W, Leoung G, Krame F, Bozett S, Safrin S, et al (1993) Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treate Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328:1521–1527
Macnab KA, Gill MJ, Sutherland LR, Visser ND, Church D (1993) Erratic zidovudine bioavailability of HIV seropositive patients. J Antimicrob Chemother 31:421–428
Fletcher CV, Rhame FS, Beatty CC, Simpson M, Balfour HH (1992) Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 12:429–434
Gatti G, Verotta D, Flaherty J, Borin M, Gamertoglio J ⊠ VIIth Int. Conf. AIDS/IIIrd STD World Congress, abstract no. PoB 3176
Gatti G, Verotta D, Flaherty J, Borin M, Gambertoglio J (1993) Absorption profile of oral clindamycin in patients with AIDS and in healthy volunteers (abstract). Clin Pharmacol Ther 53:208
Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, Fullen G, et al (1991) Safety and pharmacokinetics of 566C80, a dydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis 163:843–848
DeMuria D, Forrest A, Rich J, Scavone JM, Cohen LG, Kazanjian PH (1993) Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother 37:2187–2192
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nahata, M.C., Brady, M.T. Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. Eur J Clin Pharmacol 48, 291–293 (1995). https://doi.org/10.1007/BF00198314
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00198314